JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online January 16, 2008, 10.2967/jnumed.107.048520
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.048520v1
49/2/201    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dehdashti, F.
Right arrow Articles by Welch, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dehdashti, F.
Right arrow Articles by Welch, M. J.
Journal of Nuclear Medicine Vol. 49 No. 2 201-205
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.107.048520

Clinical Investigation

Assessing Tumor Hypoxia in Cervical Cancer by PET with 60Cu-Labeled Diacetyl-Bis(N4-Methylthiosemicarbazone)

Farrokh Dehdashti1,2, Perry W. Grigsby2,4, Jason S. Lewis2,3, Richard Laforest1,3, Barry A. Siegel1,2 and Michael J. Welch2,3

1 Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, St. Louis, Missouri; 2 Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; 3 Division of Radiological Sciences, Edward Mallinckrodt Institute of Radiology, St. Louis, Missouri; and 4 Department of Radiation Oncology, Edward Mallinckrodt Institute of Radiology, St. Louis, Missouri

Correspondence: For correspondence or reprints contact: Farrokh Dehdashti, MD, Edward Mallinckrodt Institute of Radiology, 510 South Kingshighway Blvd., St. Louis, MO 63110. E-mail: dehdashtif{at}mir.wustl.edu

Tumor hypoxia indicates a poor prognosis. This study was undertaken to confirm our prior pilot results showing that pretreatment tumor hypoxia demonstrated by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) (60Cu-ATSM) is a biomarker of poor prognosis in patients with cervical cancer. Thirty-eight women with biopsy-proved cervical cancer underwent 60Cu-ATSM PET before the initiation of radiotherapy and chemotherapy. 60Cu-ATSM uptake was evaluated semiquantitatively as the tumor-to-muscle activity ratio (T/M). A log-rank test was used to determine the cutoff uptake value that was strongly predictive of prognosis. All patients also underwent clinical PET with 18F-FDG before the institution of therapy. The PET results were correlated with clinical follow-up. Tumor 60Cu-ATSM uptake was inversely related to progression-free survival and cause-specific survival (P = 0.006 and P = 0.04, respectively, as determined by the log-rank test). We found that a T/M threshold of 3.5 best discriminated patients likely to develop a recurrence from those unlikely to develop a recurrence; the 3-y progression-free survival of patients with normoxic tumors (as defined by T/M of ≤3.5) was 71%, and that of patients with hypoxic tumors (T/M of >3.5) was 28% (P = 0.01). Tumor 18F-FDG uptake did not correlate with 60Cu-ATSM uptake, and there was no significant difference in tumor 18F-FDG uptake between patients with hypoxic tumors and those with normoxic tumors (P = 0.9). Pretherapy 60Cu-ATSM PET provides clinically relevant information about tumor oxygenation that is predictive of outcome in patients with cervical cancer.

Key Words: PET • 60Cu-ATSM • hypoxia • cervical cancer • survival

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
S. R. Bayly, R. C. King, D. J. Honess, P. J. Barnard, H. M. Betts, J. P. Holland, R. Hueting, P. D. Bonnitcha, J. R. Dilworth, F. I. Aigbirhio, et al.
In Vitro and In Vivo Evaluations of a Hydrophilic 64Cu-Bis(Thiosemicarbazonato)-Glucose Conjugate for Hypoxia Imaging
J. Nucl. Med., November 1, 2008; 49(11): 1862 - 1868.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. A. Kidd and P. W. Grigsby
Intratumoral Metabolic Heterogeneity of Cervical Cancer
Clin. Cancer Res., August 15, 2008; 14(16): 5236 - 5241.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. S. Lewis, R. Laforest, F. Dehdashti, P. W. Grigsby, M. J. Welch, and B. A. Siegel
An Imaging Comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the Uterine Cervix
J. Nucl. Med., July 1, 2008; 49(7): 1177 - 1182.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.